Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial.

ABSTRACT:

Background

There is still no clinical evidence available to support or to oppose corticosteroid treatment for coronavirus disease 2019 (COVID-19) pneumonia.

Objective

To investigate the efficacy and safety of corticosteroid given to the hospitalized patients with COVID-19 pneumonia.

Methods

This was a prospective, multicenter, single-blind, randomized control trial. Adult patients with COVID-19 pneumonia who were admitted to the general ward were randomly assigned to either receive methylprednisolone or not for 7 days. The primary end point was the incidence of clinical deterioration 14 days after randomization.

Results

We terminated this trial early because the number of patients with COVID-19 pneumonia in all the centers decreased in late March. Finally, a to

SUBMITTER: Tang X 

PROVIDER: S-EPMC7900459 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature